Oncotarget

Research Papers:

LincRNA FEZF1-AS1 contributes to the proliferation of LAD cells by silencing p57 expression

Shuai Jin, Siyu Chen, Yongfu Ma, Bo Yang and Yang Liu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:103004-103013. https://doi.org/10.18632/oncotarget.21265

Metrics: PDF 1152 views  |   HTML 2037 views  |   ?  


Abstract

Shuai Jin1, Siyu Chen1, Yongfu Ma1, Bo Yang1 and Yang Liu1

1Department of Thoracic surgery, PLA General Hospital, Beijing, 100853 China

Correspondence to:

Yang Liu, email: [email protected]

Keywords: lung adenocarcinoma, FEZF1-AS1, LSD1, EZH2, H3K4me2

Received: May 23, 2017     Accepted: September 05, 2017     Published: September 23, 2017

ABSTRACT

LincRNA FEZF1-AS1 has been identified to exert oncogenic functions in various biological processes of tumorigenesis. However, the function of FEZF1-AS1 in lung adenocarcinoma still remains unclear. Our findings revealed that FEZF1-AS1 was increased in lung adenocarcinoma tissues and cell lines and high level of FEZF1-AS1 was associated with poor prognosis of lung adenocarcinoma. Functional experiments and mechanistic investigations demonstrated that knockdown of FEZF1-AS1 significantly repressed proliferation through influencing the distribution of cell cycle. Besides, we also uncovered that FEZF1-AS1 could suppress p57 expression through recruiting EZH2 and LSD1 to the promoter of p57, thus influenced the cell cycle and proliferation. Collectively, our results suggested that FEZF1-AS1 was involved in the progression of lung adenocarcinoma and might be as a potential therapy target for human lung adenocarcinoma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21265